Australia's Orthocell climbs to 2-week high as co floats expansion plans

Orthocell

22/01/2025 04:49

** Shares of Orthocell  OCC.AX  rise 15.4% to A$1.500, their
highest levels since Jan 6
    ** The regenerative medicine firm says that it plans to
enter key markets such as Canada and Thailand, among others, in
CY2025
    ** Orthocell recently submitted its USFDA regulatory
application for the clearance to distribute its nerve drug
Remplir in the $1.6 bln (A$2.55 bln) U.S. market commercially
    ** Co expects approval in March/April 2025
    ** About 3.4 mln shares trade hands, 1.9 times the 30-day
average of 1.8 mln
    ** Stock rose 230.5% in 2024
    
    (1 Australian dollar = $0.6266)

 (Reporting by Manasi Dasa Sundeep in Bengaluru)
 ((Manasi.DasaSundeep@thomsonreuters.com;))